Shots:
- argenx has reported the topline P-II (FB102-301) trial results assessing FB102 (2 IV infusions) vs PBO in 126 adults with celiac disease who were symptom free on a strict gluten-free diet for at least 12mos.
- The trial met its 1EP, showing improvement in the Vh:Cd ratio in pts undergoing a gluten challenge. Improvements in IEL density, the VCIEL composite score & symptoms further supported efficacy across histological, inflammatory & clinical measures
- FB102 is an anti-CD122 antibody being evaluated as a potential treatment for several autoimmune diseases, incl. celiac disease, vitiligo, & alopecia areata
Ref: Globenewswire | Image: argenx | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
